At ELRIG’s 2025 meeting in GSK’s Stevenage campus, Recursion’s Executive Director of Computational Biology, Dr. Kelly ...

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant ...

Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a Fast Company “Most Innovative Company” and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a ...

Amid fierce debate about prescription-drug prices and countless proposals to rein them in, there has been a point of widespread agreement: Those prices at least partly reflect the vast amount of time, ...

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...